| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Smoking | 53 | 2020 | 484 | 4.390 |
Why?
|
| Cardiovascular Diseases | 44 | 2023 | 599 | 3.660 |
Why?
|
| Advertising as Topic | 13 | 2015 | 23 | 2.730 |
Why?
|
| Coronary Disease | 23 | 2025 | 183 | 2.450 |
Why?
|
| Smoking Cessation | 30 | 2017 | 193 | 2.420 |
Why?
|
| Humans | 220 | 2025 | 17822 | 2.280 |
Why?
|
| Diabetes Mellitus, Type 2 | 12 | 2022 | 755 | 2.190 |
Why?
|
| Male | 168 | 2025 | 10145 | 2.090 |
Why?
|
| Female | 171 | 2025 | 12780 | 1.970 |
Why?
|
| Commerce | 8 | 2017 | 48 | 1.850 |
Why?
|
| Middle Aged | 141 | 2025 | 8020 | 1.840 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 6 | 2017 | 172 | 1.660 |
Why?
|
| Adult | 134 | 2025 | 7708 | 1.640 |
Why?
|
| Aged | 97 | 2025 | 6173 | 1.620 |
Why?
|
| Tobacco Industry | 6 | 2011 | 8 | 1.610 |
Why?
|
| California | 69 | 2025 | 2328 | 1.500 |
Why?
|
| Marketing | 5 | 2017 | 20 | 1.440 |
Why?
|
| Coronary Artery Disease | 14 | 2015 | 134 | 1.360 |
Why?
|
| Health Education | 25 | 2013 | 111 | 1.290 |
Why?
|
| Primary Prevention | 6 | 2017 | 73 | 1.240 |
Why?
|
| Adolescent | 54 | 2024 | 3690 | 1.220 |
Why?
|
| Schools | 4 | 2017 | 87 | 1.220 |
Why?
|
| Cross-Sectional Studies | 47 | 2024 | 1335 | 1.150 |
Why?
|
| Health Knowledge, Attitudes, Practice | 15 | 2025 | 382 | 1.100 |
Why?
|
| Myocardial Infarction | 15 | 2016 | 238 | 1.070 |
Why?
|
| Stroke | 6 | 2025 | 315 | 1.050 |
Why?
|
| Delivery of Health Care, Integrated | 2 | 2022 | 537 | 1.040 |
Why?
|
| Risk Factors | 56 | 2025 | 3362 | 1.020 |
Why?
|
| Health Surveys | 8 | 2019 | 261 | 0.990 |
Why?
|
| Smoking Prevention | 16 | 2015 | 54 | 0.980 |
Why?
|
| European Continental Ancestry Group | 21 | 2013 | 529 | 0.950 |
Why?
|
| Hypercholesterolemia | 7 | 2016 | 32 | 0.940 |
Why?
|
| Nicotine | 19 | 2010 | 50 | 0.940 |
Why?
|
| Minerals | 2 | 2014 | 10 | 0.900 |
Why?
|
| Metabolic Syndrome | 7 | 2010 | 81 | 0.890 |
Why?
|
| Motor Activity | 5 | 2015 | 212 | 0.880 |
Why?
|
| Dietary Supplements | 2 | 2014 | 87 | 0.870 |
Why?
|
| Vitamins | 2 | 2014 | 64 | 0.860 |
Why?
|
| Surveys and Questionnaires | 18 | 2025 | 1323 | 0.840 |
Why?
|
| Adolescent Behavior | 7 | 2016 | 127 | 0.820 |
Why?
|
| Health Policy | 6 | 2020 | 123 | 0.820 |
Why?
|
| Cholesterol, HDL | 10 | 2016 | 81 | 0.810 |
Why?
|
| Tobacco Products | 3 | 2017 | 17 | 0.810 |
Why?
|
| Glycated Hemoglobin A | 4 | 2022 | 216 | 0.800 |
Why?
|
| Community Health Centers | 3 | 2020 | 64 | 0.790 |
Why?
|
| Counseling | 7 | 2017 | 189 | 0.760 |
Why?
|
| Hispanic Americans | 14 | 2013 | 404 | 0.740 |
Why?
|
| Cholesterol | 20 | 2003 | 106 | 0.740 |
Why?
|
| Hypertension | 21 | 2022 | 505 | 0.720 |
Why?
|
| Prediabetic State | 1 | 2021 | 56 | 0.720 |
Why?
|
| Exercise | 6 | 2021 | 495 | 0.720 |
Why?
|
| Accelerometry | 1 | 2021 | 39 | 0.720 |
Why?
|
| Polymorphism, Single Nucleotide | 12 | 2015 | 379 | 0.680 |
Why?
|
| Tobacco Use Cessation | 2 | 2016 | 22 | 0.680 |
Why?
|
| Ethnic Groups | 11 | 2019 | 485 | 0.670 |
Why?
|
| Documentation | 1 | 2020 | 42 | 0.670 |
Why?
|
| Prevalence | 21 | 2023 | 888 | 0.660 |
Why?
|
| Chronic Disease | 4 | 2019 | 428 | 0.660 |
Why?
|
| Safety-net Providers | 1 | 2020 | 52 | 0.650 |
Why?
|
| Educational Status | 18 | 2006 | 200 | 0.640 |
Why?
|
| Railroads | 1 | 2019 | 4 | 0.640 |
Why?
|
| Tobacco | 3 | 2011 | 14 | 0.630 |
Why?
|
| Neoplasms | 2 | 2014 | 445 | 0.630 |
Why?
|
| Sex Factors | 27 | 2016 | 644 | 0.620 |
Why?
|
| Biomarkers | 13 | 2016 | 310 | 0.600 |
Why?
|
| Environment Design | 1 | 2019 | 64 | 0.600 |
Why?
|
| Atherosclerosis | 2 | 2016 | 53 | 0.580 |
Why?
|
| Body Mass Index | 19 | 2024 | 967 | 0.570 |
Why?
|
| Blood Glucose | 4 | 2022 | 349 | 0.570 |
Why?
|
| Case-Control Studies | 18 | 2019 | 1120 | 0.570 |
Why?
|
| Meaningful Use | 1 | 2017 | 5 | 0.560 |
Why?
|
| Centers for Medicare and Medicaid Services (U.S.) | 1 | 2017 | 5 | 0.560 |
Why?
|
| Marijuana Use | 1 | 2017 | 37 | 0.550 |
Why?
|
| Obesity | 18 | 2024 | 842 | 0.550 |
Why?
|
| Asian Americans | 10 | 2013 | 176 | 0.550 |
Why?
|
| Hypertriglyceridemia | 1 | 2016 | 13 | 0.540 |
Why?
|
| Follow-Up Studies | 21 | 2013 | 1219 | 0.540 |
Why?
|
| Mass Screening | 7 | 2011 | 678 | 0.540 |
Why?
|
| Nicotinic Agonists | 10 | 2015 | 26 | 0.540 |
Why?
|
| Hypolipidemic Agents | 1 | 2016 | 40 | 0.540 |
Why?
|
| Calcinosis | 5 | 2010 | 40 | 0.530 |
Why?
|
| Alcohol Drinking | 4 | 2007 | 373 | 0.520 |
Why?
|
| Tobacco Smoking | 1 | 2016 | 20 | 0.520 |
Why?
|
| Child | 23 | 2024 | 2497 | 0.510 |
Why?
|
| Blood Pressure | 16 | 2011 | 303 | 0.510 |
Why?
|
| Kidney Failure, Chronic | 4 | 2011 | 151 | 0.510 |
Why?
|
| Insulin | 5 | 2020 | 213 | 0.500 |
Why?
|
| Incidence | 11 | 2025 | 1269 | 0.500 |
Why?
|
| Health Promotion | 7 | 2015 | 281 | 0.490 |
Why?
|
| Evidence-Based Medicine | 1 | 2016 | 186 | 0.490 |
Why?
|
| United States | 22 | 2023 | 4007 | 0.490 |
Why?
|
| Population Surveillance | 7 | 2015 | 264 | 0.490 |
Why?
|
| Predictive Value of Tests | 11 | 2016 | 354 | 0.480 |
Why?
|
| Retrospective Studies | 9 | 2025 | 2467 | 0.480 |
Why?
|
| Age Factors | 18 | 2016 | 923 | 0.470 |
Why?
|
| Logistic Models | 17 | 2019 | 928 | 0.470 |
Why?
|
| Patient Education as Topic | 4 | 2000 | 213 | 0.470 |
Why?
|
| Aged, 80 and over | 10 | 2020 | 1931 | 0.470 |
Why?
|
| Electronic Health Records | 2 | 2017 | 698 | 0.460 |
Why?
|
| Health Care Costs | 1 | 2016 | 229 | 0.460 |
Why?
|
| Attitude to Health | 6 | 2015 | 165 | 0.460 |
Why?
|
| Tobacco Use Disorder | 10 | 2015 | 49 | 0.460 |
Why?
|
| Cohort Studies | 24 | 2019 | 2590 | 0.460 |
Why?
|
| Hawaii | 2 | 2025 | 44 | 0.460 |
Why?
|
| African Americans | 11 | 2016 | 472 | 0.440 |
Why?
|
| Odds Ratio | 11 | 2014 | 673 | 0.430 |
Why?
|
| Sex Distribution | 9 | 2010 | 190 | 0.420 |
Why?
|
| Young Adult | 9 | 2025 | 2464 | 0.420 |
Why?
|
| Risk Assessment | 6 | 2015 | 1103 | 0.420 |
Why?
|
| Hospitalization | 4 | 2016 | 810 | 0.410 |
Why?
|
| Continental Population Groups | 7 | 2019 | 302 | 0.410 |
Why?
|
| African Continental Ancestry Group | 6 | 2013 | 162 | 0.390 |
Why?
|
| Heart | 2 | 2008 | 13 | 0.390 |
Why?
|
| Coronary Vessels | 2 | 2011 | 15 | 0.380 |
Why?
|
| Menthol | 1 | 2011 | 2 | 0.380 |
Why?
|
| Community Health Services | 7 | 2013 | 83 | 0.380 |
Why?
|
| Tibial Arteries | 1 | 2011 | 5 | 0.370 |
Why?
|
| Brachial Artery | 1 | 2011 | 6 | 0.370 |
Why?
|
| Cost-Benefit Analysis | 4 | 2022 | 250 | 0.370 |
Why?
|
| Body Weight | 12 | 2020 | 224 | 0.370 |
Why?
|
| Ankle Brachial Index | 1 | 2011 | 8 | 0.370 |
Why?
|
| Peripheral Arterial Disease | 1 | 2011 | 13 | 0.370 |
Why?
|
| Residence Characteristics | 5 | 2019 | 251 | 0.370 |
Why?
|
| Age of Onset | 3 | 2008 | 79 | 0.370 |
Why?
|
| Genetic Predisposition to Disease | 7 | 2015 | 376 | 0.360 |
Why?
|
| Metformin | 2 | 2022 | 58 | 0.360 |
Why?
|
| Aging | 3 | 2015 | 163 | 0.360 |
Why?
|
| Apolipoprotein A-I | 2 | 2000 | 4 | 0.360 |
Why?
|
| Apolipoproteins B | 2 | 2000 | 8 | 0.360 |
Why?
|
| Mental Disorders | 2 | 2010 | 280 | 0.350 |
Why?
|
| Health Behavior | 11 | 2015 | 360 | 0.350 |
Why?
|
| Diabetes Mellitus | 4 | 2003 | 487 | 0.350 |
Why?
|
| Behavior Therapy | 10 | 2015 | 146 | 0.340 |
Why?
|
| Incidental Findings | 2 | 2008 | 26 | 0.330 |
Why?
|
| Folic Acid | 3 | 2004 | 32 | 0.330 |
Why?
|
| Heart Failure | 5 | 2022 | 396 | 0.320 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2016 | 329 | 0.320 |
Why?
|
| Feeding Behavior | 3 | 1998 | 166 | 0.320 |
Why?
|
| Albuminuria | 3 | 2022 | 38 | 0.320 |
Why?
|
| Pregnancy | 8 | 2025 | 1529 | 0.320 |
Why?
|
| Health Personnel | 4 | 2021 | 126 | 0.320 |
Why?
|
| Perception | 2 | 2015 | 58 | 0.310 |
Why?
|
| Hypoglycemic Agents | 2 | 2022 | 272 | 0.310 |
Why?
|
| Reference Values | 5 | 2011 | 93 | 0.310 |
Why?
|
| Students | 2 | 2006 | 54 | 0.310 |
Why?
|
| Calcium | 2 | 2012 | 35 | 0.310 |
Why?
|
| Lung | 2 | 2008 | 62 | 0.310 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2025 | 391 | 0.310 |
Why?
|
| Socioeconomic Factors | 14 | 2016 | 630 | 0.300 |
Why?
|
| Mental Health | 1 | 2010 | 166 | 0.300 |
Why?
|
| Prospective Studies | 12 | 2023 | 1286 | 0.300 |
Why?
|
| Nutritional Sciences | 2 | 1997 | 11 | 0.290 |
Why?
|
| Pregnancy Complications | 2 | 2024 | 201 | 0.290 |
Why?
|
| Diet, Fat-Restricted | 2 | 1997 | 38 | 0.290 |
Why?
|
| Life Style | 8 | 2013 | 334 | 0.290 |
Why?
|
| Angina Pectoris | 4 | 2007 | 16 | 0.280 |
Why?
|
| Research Design | 5 | 2021 | 376 | 0.280 |
Why?
|
| Alcoholic Beverages | 1 | 2007 | 14 | 0.280 |
Why?
|
| Mass Media | 1 | 2006 | 17 | 0.270 |
Why?
|
| Oregon | 4 | 2025 | 181 | 0.270 |
Why?
|
| Leptin | 1 | 2006 | 29 | 0.270 |
Why?
|
| Dyslipidemias | 3 | 2022 | 62 | 0.270 |
Why?
|
| Urban Population | 6 | 2000 | 116 | 0.270 |
Why?
|
| Hyperinsulinism | 2 | 2003 | 10 | 0.260 |
Why?
|
| Plants, Toxic | 2 | 1999 | 2 | 0.260 |
Why?
|
| Activities of Daily Living | 1 | 2006 | 85 | 0.260 |
Why?
|
| Hyperhomocysteinemia | 2 | 2004 | 5 | 0.250 |
Why?
|
| Inflammation | 2 | 2004 | 64 | 0.240 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2012 | 211 | 0.240 |
Why?
|
| Nutrition Surveys | 5 | 2015 | 62 | 0.240 |
Why?
|
| Depressive Disorder | 2 | 2004 | 222 | 0.240 |
Why?
|
| Respiratory Syncytial Virus Vaccines | 1 | 2025 | 8 | 0.240 |
Why?
|
| Respiratory Syncytial Virus, Human | 1 | 2025 | 21 | 0.240 |
Why?
|
| Television | 3 | 2015 | 22 | 0.240 |
Why?
|
| Antibodies, Monoclonal | 1 | 2025 | 25 | 0.240 |
Why?
|
| Double-Blind Method | 11 | 2015 | 160 | 0.240 |
Why?
|
| Drug Therapy, Combination | 4 | 2022 | 115 | 0.240 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2025 | 29 | 0.230 |
Why?
|
| Risk | 9 | 2016 | 518 | 0.230 |
Why?
|
| Diet | 9 | 2015 | 366 | 0.230 |
Why?
|
| Recurrence | 13 | 2012 | 189 | 0.230 |
Why?
|
| Hormone Replacement Therapy | 2 | 2000 | 22 | 0.220 |
Why?
|
| Attitude | 3 | 2002 | 30 | 0.220 |
Why?
|
| Physical Exertion | 7 | 1996 | 22 | 0.220 |
Why?
|
| Administration, Cutaneous | 11 | 2015 | 16 | 0.220 |
Why?
|
| Population Groups | 1 | 2023 | 8 | 0.210 |
Why?
|
| Weight Loss | 4 | 2022 | 305 | 0.210 |
Why?
|
| Chromosomes, Human, Pair 15 | 2 | 2015 | 7 | 0.210 |
Why?
|
| Time Factors | 10 | 2016 | 1097 | 0.210 |
Why?
|
| Substance Withdrawal Syndrome | 10 | 2010 | 22 | 0.210 |
Why?
|
| Monoamine Oxidase Inhibitors | 2 | 2015 | 2 | 0.210 |
Why?
|
| Selegiline | 2 | 2015 | 2 | 0.210 |
Why?
|
| Lipids | 4 | 2015 | 82 | 0.210 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2025 | 146 | 0.210 |
Why?
|
| Longitudinal Studies | 10 | 2016 | 720 | 0.210 |
Why?
|
| Curriculum | 3 | 1997 | 36 | 0.210 |
Why?
|
| Hyperkalemia | 1 | 2022 | 16 | 0.200 |
Why?
|
| Child, Preschool | 4 | 2023 | 1424 | 0.200 |
Why?
|
| Clinical Trials as Topic | 5 | 2012 | 132 | 0.200 |
Why?
|
| Depression | 4 | 2003 | 506 | 0.200 |
Why?
|
| Reproducibility of Results | 5 | 2010 | 381 | 0.190 |
Why?
|
| Acute Kidney Injury | 1 | 2022 | 44 | 0.190 |
Why?
|
| Diabetes Complications | 1 | 2022 | 114 | 0.190 |
Why?
|
| Health Status Indicators | 2 | 1992 | 64 | 0.190 |
Why?
|
| Oxidoreductases Acting on CH-NH Group Donors | 1 | 2001 | 1 | 0.190 |
Why?
|
| Public Health Practice | 4 | 2013 | 13 | 0.190 |
Why?
|
| Regression Analysis | 14 | 2011 | 300 | 0.190 |
Why?
|
| Vital Signs | 1 | 2021 | 13 | 0.190 |
Why?
|
| Motivation | 7 | 2010 | 131 | 0.180 |
Why?
|
| Prognosis | 3 | 2016 | 609 | 0.180 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2000 | 27 | 0.180 |
Why?
|
| Cholesterol, LDL | 4 | 2016 | 119 | 0.180 |
Why?
|
| Bupropion | 3 | 2015 | 12 | 0.170 |
Why?
|
| Arginine | 2 | 2010 | 12 | 0.170 |
Why?
|
| Lipoprotein(a) | 2 | 1997 | 7 | 0.170 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2020 | 7 | 0.170 |
Why?
|
| Triglycerides | 5 | 2016 | 89 | 0.170 |
Why?
|
| Linear Models | 7 | 2011 | 232 | 0.170 |
Why?
|
| Vasodilation | 2 | 2011 | 8 | 0.170 |
Why?
|
| Practice Patterns, Physicians' | 4 | 2017 | 332 | 0.170 |
Why?
|
| Vaccination | 1 | 2025 | 655 | 0.170 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2019 | 7 | 0.170 |
Why?
|
| Anemia | 1 | 2020 | 34 | 0.170 |
Why?
|
| Age Distribution | 5 | 2011 | 246 | 0.170 |
Why?
|
| Statistics as Topic | 4 | 2010 | 64 | 0.170 |
Why?
|
| Forecasting | 1 | 2020 | 75 | 0.160 |
Why?
|
| Self Care | 4 | 1997 | 163 | 0.160 |
Why?
|
| Health Status | 3 | 2010 | 299 | 0.160 |
Why?
|
| Rural Health | 1 | 1999 | 8 | 0.160 |
Why?
|
| Comorbidity | 4 | 2019 | 597 | 0.160 |
Why?
|
| Happiness | 1 | 1998 | 1 | 0.160 |
Why?
|
| Diagnostic Techniques, Cardiovascular | 2 | 2012 | 2 | 0.160 |
Why?
|
| Mexican Americans | 2 | 2013 | 45 | 0.160 |
Why?
|
| Community Participation | 1 | 1999 | 30 | 0.160 |
Why?
|
| Primary Health Care | 4 | 2017 | 770 | 0.150 |
Why?
|
| Medicare | 1 | 2020 | 205 | 0.150 |
Why?
|
| Self Concept | 1 | 1998 | 39 | 0.150 |
Why?
|
| Genotype | 7 | 2008 | 227 | 0.150 |
Why?
|
| Electronic Nicotine Delivery Systems | 2 | 2015 | 32 | 0.150 |
Why?
|
| Insurance Coverage | 2 | 2016 | 106 | 0.150 |
Why?
|
| Blood Coagulation Factors | 2 | 2007 | 10 | 0.150 |
Why?
|
| Program Evaluation | 7 | 1999 | 223 | 0.140 |
Why?
|
| Carbon Monoxide | 6 | 2010 | 13 | 0.140 |
Why?
|
| Treatment Outcome | 10 | 2015 | 1265 | 0.140 |
Why?
|
| Peer Group | 2 | 2007 | 48 | 0.140 |
Why?
|
| Arteriosclerosis | 4 | 2004 | 20 | 0.140 |
Why?
|
| Ambulatory Care | 2 | 2019 | 247 | 0.140 |
Why?
|
| Fibric Acids | 1 | 2016 | 2 | 0.140 |
Why?
|
| Niacin | 1 | 2016 | 3 | 0.140 |
Why?
|
| Medicaid | 2 | 2016 | 190 | 0.140 |
Why?
|
| Social Norms | 1 | 2016 | 3 | 0.140 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2016 | 22 | 0.140 |
Why?
|
| Smokers | 1 | 2016 | 12 | 0.130 |
Why?
|
| Troponin I | 1 | 2016 | 8 | 0.130 |
Why?
|
| Medication Adherence | 2 | 2017 | 246 | 0.130 |
Why?
|
| Infant | 3 | 2025 | 1198 | 0.130 |
Why?
|
| Fetal Development | 1 | 2015 | 14 | 0.130 |
Why?
|
| Public Health | 1 | 2016 | 81 | 0.130 |
Why?
|
| Data Collection | 3 | 1994 | 257 | 0.120 |
Why?
|
| Dietary Fats | 2 | 1994 | 91 | 0.120 |
Why?
|
| Insulin Resistance | 2 | 2009 | 137 | 0.120 |
Why?
|
| Genetic Loci | 1 | 2015 | 55 | 0.120 |
Why?
|
| Public Policy | 2 | 2012 | 17 | 0.120 |
Why?
|
| Tobacco Use | 1 | 2015 | 15 | 0.120 |
Why?
|
| Physician-Patient Relations | 1 | 2017 | 189 | 0.120 |
Why?
|
| Receptors, Nicotinic | 2 | 2015 | 9 | 0.120 |
Why?
|
| Risk-Taking | 2 | 2007 | 109 | 0.120 |
Why?
|
| Comparative Effectiveness Research | 3 | 2022 | 66 | 0.120 |
Why?
|
| Diagnostic Imaging | 2 | 2012 | 45 | 0.120 |
Why?
|
| Global Health | 3 | 2015 | 33 | 0.120 |
Why?
|
| Multivariate Analysis | 4 | 2007 | 569 | 0.120 |
Why?
|
| Interviews as Topic | 2 | 1999 | 305 | 0.120 |
Why?
|
| Kidney Diseases | 2 | 2011 | 53 | 0.120 |
Why?
|
| Adiposity | 1 | 2015 | 66 | 0.120 |
Why?
|
| Practice Guidelines as Topic | 1 | 2016 | 321 | 0.120 |
Why?
|
| Substance-Related Disorders | 3 | 1996 | 434 | 0.120 |
Why?
|
| Patient-Centered Care | 1 | 2017 | 197 | 0.120 |
Why?
|
| Vulnerable Populations | 3 | 2024 | 39 | 0.120 |
Why?
|
| Patient Dropouts | 1 | 1994 | 22 | 0.120 |
Why?
|
| Fasting | 3 | 2004 | 50 | 0.120 |
Why?
|
| Disease Management | 1 | 2015 | 135 | 0.110 |
Why?
|
| Homocysteine | 2 | 2004 | 13 | 0.110 |
Why?
|
| Ascorbic Acid | 1 | 1993 | 19 | 0.110 |
Why?
|
| Health Services Needs and Demand | 1 | 2014 | 93 | 0.110 |
Why?
|
| Absenteeism | 3 | 1990 | 24 | 0.110 |
Why?
|
| Outpatients | 1 | 2014 | 110 | 0.110 |
Why?
|
| Cerebrovascular Disorders | 3 | 1995 | 34 | 0.110 |
Why?
|
| Pregnancy Outcome | 2 | 2024 | 158 | 0.110 |
Why?
|
| Epidemiologic Methods | 7 | 2003 | 81 | 0.110 |
Why?
|
| Tobacco Smoke Pollution | 1 | 1993 | 34 | 0.110 |
Why?
|
| Circadian Rhythm | 1 | 1993 | 17 | 0.110 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2022 | 86 | 0.110 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 1993 | 16 | 0.110 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2015 | 167 | 0.110 |
Why?
|
| Models, Statistical | 2 | 2012 | 178 | 0.110 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2015 | 181 | 0.110 |
Why?
|
| Administrative Personnel | 1 | 2013 | 6 | 0.110 |
Why?
|
| Antihypertensive Agents | 1 | 2014 | 161 | 0.110 |
Why?
|
| Pyridoxine | 2 | 2004 | 2 | 0.100 |
Why?
|
| Occupations | 2 | 1992 | 16 | 0.100 |
Why?
|
| Vitamin B 12 | 2 | 2004 | 15 | 0.100 |
Why?
|
| Proteinuria | 1 | 2012 | 26 | 0.100 |
Why?
|
| Physician's Role | 2 | 1991 | 31 | 0.100 |
Why?
|
| Diabetic Nephropathies | 1 | 2012 | 26 | 0.100 |
Why?
|
| San Francisco | 3 | 2016 | 64 | 0.100 |
Why?
|
| Terminology as Topic | 1 | 2012 | 17 | 0.100 |
Why?
|
| Delivery of Health Care | 2 | 2015 | 417 | 0.100 |
Why?
|
| Myocardial Ischemia | 1 | 2012 | 24 | 0.100 |
Why?
|
| Homeless Persons | 1 | 1992 | 26 | 0.100 |
Why?
|
| Anticholesteremic Agents | 1 | 1992 | 14 | 0.100 |
Why?
|
| Physicians, Family | 1 | 1992 | 44 | 0.100 |
Why?
|
| Polymethacrylic Acids | 2 | 1990 | 2 | 0.100 |
Why?
|
| Polyvinyls | 2 | 1990 | 2 | 0.100 |
Why?
|
| Cardiology | 1 | 2012 | 30 | 0.100 |
Why?
|
| Nitroglycerin | 2 | 2011 | 6 | 0.100 |
Why?
|
| Uncertainty | 1 | 2012 | 7 | 0.100 |
Why?
|
| Magnetic Resonance Angiography | 2 | 2011 | 8 | 0.100 |
Why?
|
| Vasodilator Agents | 2 | 2011 | 9 | 0.100 |
Why?
|
| Social Environment | 2 | 2016 | 88 | 0.100 |
Why?
|
| Income | 1 | 1992 | 90 | 0.100 |
Why?
|
| Angina, Stable | 1 | 2011 | 4 | 0.100 |
Why?
|
| Sitagliptin Phosphate | 2 | 2022 | 3 | 0.090 |
Why?
|
| Intention | 2 | 2015 | 28 | 0.090 |
Why?
|
| Liraglutide | 2 | 2022 | 5 | 0.090 |
Why?
|
| 1-Alkyl-2-acetylglycerophosphocholine Esterase | 1 | 2011 | 5 | 0.090 |
Why?
|
| Cardiovascular Agents | 1 | 2011 | 24 | 0.090 |
Why?
|
| Coronary Circulation | 1 | 2011 | 4 | 0.090 |
Why?
|
| Ultrasonography, Doppler | 1 | 2011 | 5 | 0.090 |
Why?
|
| Thiocyanates | 3 | 1988 | 4 | 0.090 |
Why?
|
| Sulfonylurea Compounds | 2 | 2022 | 25 | 0.090 |
Why?
|
| Protein Subunits | 1 | 2011 | 1 | 0.090 |
Why?
|
| Multigene Family | 1 | 2011 | 7 | 0.090 |
Why?
|
| Glomerular Filtration Rate | 3 | 2022 | 154 | 0.090 |
Why?
|
| Tryptophan | 1 | 2010 | 3 | 0.090 |
Why?
|
| Kinesin | 1 | 2010 | 3 | 0.090 |
Why?
|
| Poverty | 3 | 1997 | 167 | 0.090 |
Why?
|
| Occupational Health Services | 2 | 1987 | 15 | 0.090 |
Why?
|
| Hyperlipidemias | 2 | 2000 | 54 | 0.090 |
Why?
|
| Analysis of Variance | 5 | 2007 | 159 | 0.090 |
Why?
|
| Chewing Gum | 5 | 1996 | 8 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2010 | 107 | 0.090 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 50 | 0.080 |
Why?
|
| Confounding Factors (Epidemiology) | 3 | 2007 | 86 | 0.080 |
Why?
|
| Psychometrics | 1 | 2010 | 121 | 0.080 |
Why?
|
| Electrocardiography | 4 | 2012 | 42 | 0.080 |
Why?
|
| Gene Frequency | 4 | 2011 | 43 | 0.080 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 2008 | 4 | 0.080 |
Why?
|
| Alcoholism | 1 | 1992 | 348 | 0.080 |
Why?
|
| Random Allocation | 4 | 1996 | 37 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2008 | 7 | 0.080 |
Why?
|
| Mental Recall | 2 | 2007 | 31 | 0.080 |
Why?
|
| Scavenger Receptors, Class E | 1 | 2008 | 3 | 0.080 |
Why?
|
| Arachidonate 5-Lipoxygenase | 1 | 2008 | 4 | 0.080 |
Why?
|
| Carrier Proteins | 1 | 2008 | 13 | 0.080 |
Why?
|
| Energy Metabolism | 3 | 2006 | 51 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2020 | 129 | 0.070 |
Why?
|
| Platelet Membrane Glycoproteins | 1 | 2007 | 3 | 0.070 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2007 | 3 | 0.070 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2007 | 4 | 0.070 |
Why?
|
| Physicians | 3 | 1985 | 138 | 0.070 |
Why?
|
| Matrix Metalloproteinases | 1 | 2007 | 5 | 0.070 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2007 | 7 | 0.070 |
Why?
|
| Membrane Proteins | 1 | 2008 | 39 | 0.070 |
Why?
|
| Arachidonate 12-Lipoxygenase | 1 | 2007 | 4 | 0.070 |
Why?
|
| Arachidonate 15-Lipoxygenase | 1 | 2007 | 4 | 0.070 |
Why?
|
| Recognition (Psychology) | 1 | 2007 | 1 | 0.070 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2007 | 4 | 0.070 |
Why?
|
| Chemokines | 1 | 2007 | 8 | 0.070 |
Why?
|
| Community Health Planning | 2 | 2008 | 19 | 0.070 |
Why?
|
| Alleles | 3 | 2015 | 85 | 0.070 |
Why?
|
| Endarterectomy, Carotid | 1 | 2007 | 6 | 0.070 |
Why?
|
| Carotid Artery Diseases | 1 | 2007 | 13 | 0.070 |
Why?
|
| Utilization Review | 1 | 2007 | 53 | 0.070 |
Why?
|
| Self Disclosure | 1 | 2007 | 22 | 0.070 |
Why?
|
| Evaluation Studies as Topic | 4 | 1993 | 33 | 0.070 |
Why?
|
| Parenting | 1 | 2007 | 29 | 0.070 |
Why?
|
| Developing Countries | 2 | 2003 | 16 | 0.070 |
Why?
|
| ROC Curve | 1 | 2006 | 77 | 0.070 |
Why?
|
| Leisure Activities | 1 | 2006 | 31 | 0.070 |
Why?
|
| Exploratory Behavior | 1 | 2006 | 1 | 0.070 |
Why?
|
| Social Perception | 1 | 2006 | 4 | 0.070 |
Why?
|
| Occupational Diseases | 1 | 1986 | 41 | 0.060 |
Why?
|
| Emigration and Immigration | 1 | 2006 | 15 | 0.060 |
Why?
|
| Psychology, Adolescent | 1 | 2006 | 14 | 0.060 |
Why?
|
| Models, Psychological | 1 | 2006 | 23 | 0.060 |
Why?
|
| Overweight | 2 | 2024 | 270 | 0.060 |
Why?
|
| Chi-Square Distribution | 4 | 2011 | 154 | 0.060 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2006 | 43 | 0.060 |
Why?
|
| Sampling Studies | 4 | 1994 | 52 | 0.060 |
Why?
|
| Sensitivity and Specificity | 1 | 2006 | 305 | 0.060 |
Why?
|
| Craving | 2 | 2015 | 11 | 0.060 |
Why?
|
| Death Certificates | 2 | 2000 | 19 | 0.060 |
Why?
|
| Patient Readmission | 1 | 2007 | 164 | 0.060 |
Why?
|
| Renal Dialysis | 2 | 2004 | 57 | 0.060 |
Why?
|
| Telephone | 3 | 1999 | 161 | 0.060 |
Why?
|
| Infant, Newborn | 2 | 2024 | 858 | 0.060 |
Why?
|
| C-Reactive Protein | 1 | 2004 | 59 | 0.060 |
Why?
|
| Paroxetine | 2 | 2003 | 23 | 0.060 |
Why?
|
| Physical Examination | 1 | 2004 | 20 | 0.060 |
Why?
|
| Antidepressive Agents, Second-Generation | 2 | 2003 | 28 | 0.060 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2024 | 17 | 0.060 |
Why?
|
| Health Services Research | 2 | 2016 | 232 | 0.060 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2004 | 125 | 0.060 |
Why?
|
| Patient Compliance | 4 | 2008 | 301 | 0.060 |
Why?
|
| Algorithms | 3 | 2007 | 239 | 0.060 |
Why?
|
| Washington | 1 | 2025 | 383 | 0.060 |
Why?
|
| Asymptomatic Diseases | 2 | 2016 | 29 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 1 | 2004 | 86 | 0.050 |
Why?
|
| Bias | 2 | 1996 | 103 | 0.050 |
Why?
|
| Breath Tests | 3 | 2010 | 8 | 0.050 |
Why?
|
| Estrogens | 1 | 1983 | 61 | 0.050 |
Why?
|
| Genetic Markers | 2 | 2015 | 25 | 0.050 |
Why?
|
| Dietary Proteins | 1 | 2003 | 20 | 0.050 |
Why?
|
| Attitude of Health Personnel | 1 | 1985 | 214 | 0.050 |
Why?
|
| World Health Organization | 3 | 2001 | 14 | 0.050 |
Why?
|
| Biomedical Research | 1 | 2003 | 86 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2015 | 129 | 0.050 |
Why?
|
| Microvessels | 1 | 2022 | 1 | 0.050 |
Why?
|
| Family Practice | 1 | 2003 | 45 | 0.050 |
Why?
|
| Insulin Glargine | 1 | 2022 | 9 | 0.050 |
Why?
|
| Potassium | 1 | 2022 | 16 | 0.050 |
Why?
|
| Multimorbidity | 1 | 2022 | 14 | 0.050 |
Why?
|
| Diabetic Neuropathies | 1 | 2022 | 13 | 0.050 |
Why?
|
| Anxiety | 1 | 2003 | 151 | 0.050 |
Why?
|
| Generalization (Psychology) | 1 | 2001 | 1 | 0.050 |
Why?
|
| Tobacco, Smokeless | 1 | 2001 | 2 | 0.050 |
Why?
|
| Antiviral Agents | 1 | 2022 | 95 | 0.050 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2022 | 53 | 0.050 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2001 | 9 | 0.050 |
Why?
|
| Peritoneal Dialysis | 1 | 2001 | 7 | 0.050 |
Why?
|
| Saliva | 2 | 1999 | 12 | 0.050 |
Why?
|
| Diet Surveys | 1 | 1981 | 57 | 0.050 |
Why?
|
| Animals | 2 | 2015 | 262 | 0.050 |
Why?
|
| Blood Pressure Determination | 1 | 1981 | 57 | 0.050 |
Why?
|
| Community Mental Health Services | 1 | 2001 | 33 | 0.050 |
Why?
|
| Internet | 1 | 2023 | 231 | 0.050 |
Why?
|
| Quality Assurance, Health Care | 2 | 2012 | 169 | 0.050 |
Why?
|
| Drug Tolerance | 2 | 1999 | 4 | 0.050 |
Why?
|
| Mutation | 1 | 2001 | 131 | 0.050 |
Why?
|
| Epidemiologic Studies | 1 | 2000 | 29 | 0.040 |
Why?
|
| American Heart Association | 2 | 2013 | 49 | 0.040 |
Why?
|
| Transferrins | 1 | 2020 | 4 | 0.040 |
Why?
|
| Transferrin | 1 | 2020 | 5 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 1 | 2020 | 3 | 0.040 |
Why?
|
| Calibration | 1 | 2020 | 8 | 0.040 |
Why?
|
| Menopause | 1 | 2000 | 69 | 0.040 |
Why?
|
| Ferritins | 1 | 2020 | 9 | 0.040 |
Why?
|
| Asian Continental Ancestry Group | 2 | 2011 | 90 | 0.040 |
Why?
|
| Morbidity | 1 | 2020 | 59 | 0.040 |
Why?
|
| Hemoglobins | 1 | 2020 | 39 | 0.040 |
Why?
|
| Genome-Wide Association Study | 2 | 2011 | 249 | 0.040 |
Why?
|
| Linkage Disequilibrium | 2 | 2011 | 30 | 0.040 |
Why?
|
| Postmenopause | 1 | 2000 | 243 | 0.040 |
Why?
|
| Asia | 2 | 2011 | 15 | 0.040 |
Why?
|
| Decision Making | 2 | 2017 | 184 | 0.040 |
Why?
|
| Cholesterol, Dietary | 2 | 1993 | 10 | 0.040 |
Why?
|
| Diet, Reducing | 2 | 1988 | 25 | 0.040 |
Why?
|
| Lipoproteins, LDL | 2 | 1996 | 15 | 0.040 |
Why?
|
| Risk Reduction Behavior | 2 | 2013 | 108 | 0.040 |
Why?
|
| Urban Health | 2 | 1995 | 38 | 0.040 |
Why?
|
| Medical Records | 2 | 2010 | 100 | 0.040 |
Why?
|
| Outcome and Process Assessment (Health Care) | 2 | 2017 | 102 | 0.040 |
Why?
|
| Manuals as Topic | 1 | 1997 | 7 | 0.040 |
Why?
|
| Video Recording | 1 | 1997 | 12 | 0.040 |
Why?
|
| Apolipoproteins A | 1 | 1997 | 2 | 0.030 |
Why?
|
| Physical Fitness | 3 | 1993 | 73 | 0.030 |
Why?
|
| Communication | 1 | 1998 | 194 | 0.030 |
Why?
|
| Proportional Hazards Models | 2 | 2015 | 711 | 0.030 |
Why?
|
| Weight Gain | 3 | 1999 | 173 | 0.030 |
Why?
|
| Myocardial Revascularization | 2 | 2012 | 12 | 0.030 |
Why?
|
| Non-ST Elevated Myocardial Infarction | 1 | 2016 | 8 | 0.030 |
Why?
|
| Combined Modality Therapy | 4 | 1992 | 147 | 0.030 |
Why?
|
| Motivational Interviewing | 1 | 2017 | 33 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2016 | 7 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2015 | 19 | 0.030 |
Why?
|
| Varenicline | 1 | 2015 | 13 | 0.030 |
Why?
|
| Models, Biological | 1 | 2015 | 30 | 0.030 |
Why?
|
| Pulse | 2 | 1993 | 7 | 0.030 |
Why?
|
| Matched-Pair Analysis | 1 | 1995 | 10 | 0.030 |
Why?
|
| Internal-External Control | 1 | 1995 | 12 | 0.030 |
Why?
|
| Waist Circumference | 1 | 2015 | 39 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2009 | 17 | 0.030 |
Why?
|
| Propensity Score | 1 | 2015 | 85 | 0.030 |
Why?
|
| Death, Sudden, Cardiac | 2 | 2006 | 35 | 0.030 |
Why?
|
| Financing, Organized | 1 | 1994 | 5 | 0.030 |
Why?
|
| Abortion, Induced | 1 | 1975 | 18 | 0.030 |
Why?
|
| Acculturation | 1 | 1994 | 20 | 0.030 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2014 | 42 | 0.030 |
Why?
|
| Energy Intake | 1 | 1994 | 101 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1993 | 10 | 0.030 |
Why?
|
| Health Status Disparities | 1 | 2015 | 147 | 0.030 |
Why?
|
| Occupational Health | 1 | 2013 | 17 | 0.030 |
Why?
|
| Survival Analysis | 3 | 1999 | 216 | 0.030 |
Why?
|
| Goals | 1 | 2013 | 30 | 0.030 |
Why?
|
| Oceanic Ancestry Group | 1 | 2013 | 33 | 0.030 |
Why?
|
| Foster Home Care | 1 | 1992 | 5 | 0.030 |
Why?
|
| Cardiovascular Surgical Procedures | 1 | 2012 | 2 | 0.030 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2012 | 2 | 0.030 |
Why?
|
| Prosthesis Failure | 1 | 2012 | 3 | 0.030 |
Why?
|
| Intraoperative Complications | 1 | 2012 | 5 | 0.030 |
Why?
|
| Stents | 1 | 2012 | 11 | 0.030 |
Why?
|
| Cardiac Imaging Techniques | 1 | 2012 | 3 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2012 | 60 | 0.030 |
Why?
|
| Faculty, Medical | 1 | 1992 | 8 | 0.030 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2012 | 32 | 0.030 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2012 | 22 | 0.030 |
Why?
|
| Internal Medicine | 1 | 1992 | 20 | 0.030 |
Why?
|
| Coronary Artery Bypass | 1 | 2012 | 27 | 0.030 |
Why?
|
| Preventive Medicine | 1 | 1992 | 24 | 0.020 |
Why?
|
| Sample Size | 1 | 2012 | 29 | 0.020 |
Why?
|
| Licensure | 1 | 1992 | 5 | 0.020 |
Why?
|
| Policy Making | 1 | 1992 | 15 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2014 | 292 | 0.020 |
Why?
|
| Child Abuse | 1 | 1992 | 44 | 0.020 |
Why?
|
| Africa | 1 | 2011 | 6 | 0.020 |
Why?
|
| Clinical Competence | 1 | 1992 | 100 | 0.020 |
Why?
|
| Critical Care | 1 | 2012 | 71 | 0.020 |
Why?
|
| Seasons | 1 | 1992 | 105 | 0.020 |
Why?
|
| Europe | 1 | 2011 | 42 | 0.020 |
Why?
|
| Nitric Oxide Donors | 1 | 2011 | 3 | 0.020 |
Why?
|
| Severity of Illness Index | 2 | 2008 | 455 | 0.020 |
Why?
|
| Observer Variation | 1 | 2010 | 37 | 0.020 |
Why?
|
| Internationality | 1 | 2010 | 14 | 0.020 |
Why?
|
| Demography | 1 | 2011 | 101 | 0.020 |
Why?
|
| Cystatin C | 1 | 2009 | 15 | 0.020 |
Why?
|
| Sex Characteristics | 2 | 2002 | 69 | 0.020 |
Why?
|
| Social Class | 1 | 1990 | 121 | 0.020 |
Why?
|
| Lipoproteins | 1 | 1988 | 14 | 0.020 |
Why?
|
| Probability | 2 | 1996 | 79 | 0.020 |
Why?
|
| Patient Participation | 1 | 1990 | 134 | 0.020 |
Why?
|
| Oxygen Consumption | 1 | 1988 | 10 | 0.020 |
Why?
|
| Respiration | 1 | 1988 | 8 | 0.020 |
Why?
|
| 5-Lipoxygenase-Activating Proteins | 1 | 2008 | 4 | 0.020 |
Why?
|
| Monitoring, Physiologic | 1 | 1988 | 40 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2008 | 15 | 0.020 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2008 | 12 | 0.020 |
Why?
|
| Molecular Epidemiology | 1 | 2008 | 44 | 0.020 |
Why?
|
| Disease Progression | 1 | 2009 | 267 | 0.020 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2007 | 3 | 0.020 |
Why?
|
| Fibrinogen | 1 | 2007 | 13 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2007 | 8 | 0.020 |
Why?
|
| Disease Susceptibility | 1 | 2007 | 37 | 0.020 |
Why?
|
| Mutagenesis | 1 | 2007 | 5 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2007 | 16 | 0.020 |
Why?
|
| Kidney Neoplasms | 1 | 2007 | 16 | 0.020 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2007 | 23 | 0.020 |
Why?
|
| Protein Array Analysis | 1 | 2007 | 5 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2007 | 34 | 0.020 |
Why?
|
| Mice | 1 | 2007 | 69 | 0.020 |
Why?
|
| Dietary Fats, Unsaturated | 1 | 1987 | 5 | 0.020 |
Why?
|
| Elective Surgical Procedures | 1 | 2007 | 8 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2007 | 81 | 0.020 |
Why?
|
| Adipose Tissue | 1 | 1987 | 64 | 0.020 |
Why?
|
| Brain Ischemia | 1 | 2007 | 37 | 0.020 |
Why?
|
| Social Identification | 1 | 1986 | 7 | 0.020 |
Why?
|
| Psychology, Social | 1 | 1986 | 3 | 0.020 |
Why?
|
| Delayed-Action Preparations | 1 | 2006 | 6 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2007 | 230 | 0.020 |
Why?
|
| Placenta Previa | 1 | 2006 | 3 | 0.020 |
Why?
|
| Mexico | 1 | 2006 | 19 | 0.020 |
Why?
|
| Pregnancy in Adolescence | 1 | 2006 | 8 | 0.020 |
Why?
|
| Infant Mortality | 1 | 2006 | 20 | 0.020 |
Why?
|
| Infant, Low Birth Weight | 1 | 2006 | 35 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 1986 | 80 | 0.020 |
Why?
|
| Maternal Age | 1 | 2006 | 77 | 0.020 |
Why?
|
| Outcome Assessment (Health Care) | 1 | 2007 | 228 | 0.020 |
Why?
|
| Infant, Premature | 1 | 2006 | 60 | 0.020 |
Why?
|
| Hypertension, Pregnancy-Induced | 1 | 2006 | 46 | 0.020 |
Why?
|
| Prenatal Care | 1 | 2006 | 130 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2008 | 260 | 0.010 |
Why?
|
| Proinsulin | 1 | 2004 | 1 | 0.010 |
Why?
|
| Hospitals, Veterans | 1 | 2004 | 34 | 0.010 |
Why?
|
| Glucose Tolerance Test | 1 | 2004 | 111 | 0.010 |
Why?
|
| Contraceptives, Oral | 1 | 1983 | 26 | 0.010 |
Why?
|
| Stress, Psychological | 3 | 1993 | 141 | 0.010 |
Why?
|
| Albumins | 1 | 2003 | 6 | 0.010 |
Why?
|
| Acute Disease | 1 | 2003 | 144 | 0.010 |
Why?
|
| Models, Cardiovascular | 1 | 2003 | 5 | 0.010 |
Why?
|
| Creatinine | 1 | 2003 | 65 | 0.010 |
Why?
|
| Cause of Death | 1 | 2004 | 181 | 0.010 |
Why?
|
| Secondary Prevention | 1 | 2003 | 48 | 0.010 |
Why?
|
| Research | 1 | 2003 | 65 | 0.010 |
Why?
|
| Patient Selection | 1 | 2004 | 190 | 0.010 |
Why?
|
| Rural Population | 1 | 1982 | 52 | 0.010 |
Why?
|
| Language | 1 | 1982 | 53 | 0.010 |
Why?
|
| Needs Assessment | 1 | 2001 | 69 | 0.010 |
Why?
|
| Behavior, Addictive | 1 | 1999 | 12 | 0.010 |
Why?
|
| Registries | 1 | 2000 | 472 | 0.010 |
Why?
|
| Isomerism | 1 | 1997 | 3 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1996 | 5 | 0.010 |
Why?
|
| Coronary Angiography | 1 | 1996 | 21 | 0.010 |
Why?
|
| Thrombolytic Therapy | 1 | 1996 | 20 | 0.010 |
Why?
|
| India | 1 | 1995 | 13 | 0.010 |
Why?
|
| Japan | 1 | 1995 | 15 | 0.010 |
Why?
|
| Poisson Distribution | 1 | 1995 | 88 | 0.010 |
Why?
|
| China | 1 | 1995 | 132 | 0.010 |
Why?
|
| Jurisprudence | 1 | 1975 | 1 | 0.010 |
Why?
|
| Legislation as Topic | 1 | 1975 | 1 | 0.010 |
Why?
|
| Women's Rights | 1 | 1975 | 1 | 0.010 |
Why?
|
| Life | 1 | 1975 | 1 | 0.010 |
Why?
|
| Beginning of Human Life | 1 | 1975 | 1 | 0.010 |
Why?
|
| Supreme Court Decisions | 1 | 1975 | 1 | 0.010 |
Why?
|
| Privacy | 1 | 1975 | 5 | 0.010 |
Why?
|
| Fetus | 1 | 1975 | 6 | 0.010 |
Why?
|
| Value of Life | 1 | 1975 | 5 | 0.010 |
Why?
|
| Birth Rate | 1 | 1975 | 5 | 0.010 |
Why?
|
| Public Opinion | 1 | 1975 | 6 | 0.010 |
Why?
|
| Contraception | 1 | 1975 | 25 | 0.010 |
Why?
|
| Organizational Objectives | 1 | 1994 | 18 | 0.010 |
Why?
|
| Pregnant Women | 1 | 1975 | 45 | 0.010 |
Why?
|
| Heart Diseases | 1 | 1994 | 77 | 0.010 |
Why?
|
| Teaching | 1 | 1992 | 14 | 0.010 |
Why?
|
| Internship and Residency | 1 | 1992 | 46 | 0.010 |
Why?
|
| Models, Theoretical | 1 | 1992 | 70 | 0.010 |
Why?
|
| Rest | 1 | 1991 | 3 | 0.010 |
Why?
|
| Heart Rate | 1 | 1991 | 41 | 0.010 |
Why?
|
| Affect | 1 | 1991 | 25 | 0.010 |
Why?
|
| Hunger | 1 | 1990 | 5 | 0.010 |
Why?
|
| Jogging | 1 | 1988 | 2 | 0.000 |
Why?
|
| Family | 1 | 1988 | 112 | 0.000 |
Why?
|
| Habits | 1 | 1986 | 7 | 0.000 |
Why?
|
| Type A Personality | 1 | 1986 | 4 | 0.000 |
Why?
|
| Lipoproteins, HDL | 1 | 1986 | 7 | 0.000 |
Why?
|
| Relaxation Therapy | 1 | 1986 | 5 | 0.000 |
Why?
|
| Body Height | 1 | 1986 | 62 | 0.000 |
Why?
|
| Marriage | 1 | 1985 | 5 | 0.000 |
Why?
|
| Anthropometry | 1 | 1985 | 66 | 0.000 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 1984 | 27 | 0.000 |
Why?
|